Zydus Cadila, India leading pharmaceutical giant on Wednesday announces its plasmid DNA Covid-19 vaccine, ZyCoV-D has safely done its job in its Phase-I human trial on healthy subjects which initiated on 15th of July.
The Zydus Cadila company announces that, “plasmid DNA vaccine to prevent Covid-19, ZyCoV-D was found to be safe and well tolerated in the Phase I clinical trial”. Pankaj R Patel, Chairman, Zydus Cadila states that, “The Phase-I dosing to establish the safety of ZyCoV-D is an important milestone. All the subjects in Phase-I clinical trial were closely monitored in a clinical pharmacological unit for 24 hours post dosing for safety and for 7 days thereafter and vaccine was found to be very safe. We now begin the Phase-II clinical trials and look forward to evaluating the safety and immunogenicity of the vaccine in a larger population,” he added.
The Phase-II trial will commence from 6th of August. The Phase II study will be conducted in over 1,000 healthy adult volunteers as per the Adaptive Phase I/II dose escalation, multicentric, randomised, double-blind placebo controlled study will then evaluate the humoral and cellular immune responses and for its longevity for 6 months at minimum.
